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   A series of thiophene-2-carboxylic acids and thiophene-3-carboxylic acids 17 
were identified as a new class of DAO inhibitors. Structure-activity relationship 18 
(SAR) studies revealed that small substituents are well-tolerated on the 19 
thiophene ring of both the 2-carboxylic acid and 3-carboxylic acid scaffolds. 20 
Crystal structures of human DAO in complex with potent thiophene carboxylic 21 
acids revealed that Tyr224 was tightly stacked with the thiophene ring of the 22 
inhibitors, resulting in the disappearance of the secondary pocket observed with 23 
other DAO inhibitors. Molecular dynamics simulations of the complex revealed 24 
that Tyr224 preferred the stacked conformation irrespective of whether Tyr224 25 
was stacked or not in the initial state of the simulations. MM/GBSA indicated a 26 
substantial hydrophobic interaction between Tyr244 and the thiophene-based 27 
inhibitor. In addition, the active site was tightly closed with an extensive network 28 
of hydrogen bonds including those from Tyr224 in the stacked conformation. The 29 
introduction of a large branched side chain to the thiophene ring markedly 30 
decreased potency. These results are in marked contrast to other DAO inhibitors 31 
that can gain potency with a branched side chain extending to the secondary 32 
pocket due to Tyr224 repositioning. These insights should be of particular 33 
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importance in future efforts to optimize DAO inhibitors with novel scaffolds. 1 
2 
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· Therapeutics with DAO/DAAO inhibition is a potential approach to treat8 
schizophrenia. 9 
· Thiophene carboxylic acids were identified as a new class of DAO inhibitors.10 
· Tyr224 of DAO was tightly stacked with the thiophene ring of the inhibitors.11 
· The hydrophobic interaction and hydrogen bonds between them induced the12 
stacking. 13 
· The results should be important in future efforts to optimize DAO inhibitors.14 
15 
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D-Amino acid oxidase (DAO/DAAO) is a flavoenzyme that catalyzes the25 
oxidation of D-amino acids, producing the corresponding α-keto acids, ammonia, 26 
and hydrogen peroxide [1]. One of the endogenous substrates for DAO in the 27 
brain is the co-agonist of NMDA receptors, D-serine (D-Ser) [2-4]. In the brains 28 
of patients with schizophrenia, the amount of D-Ser decreases presumably due 29 
to increased DAO activity [5-10]. Since NMDA receptor hypofunction is believed 30 
to play a pathophysiological role in the negative symptoms and cognitive 31 
impairment of schizophrenia, inhibition of DAO has been of great interest as a 32 
therapeutic approach distinct from those targeting dopaminergic pathways 33 
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[11-13]. Indeed, the past decade has seen a wave of medicinal chemistry efforts 1 
in the search for new DAO inhibitors [14, 15].  2 
   Nearly all DAO inhibitors possess a carboxylic acid or its bioisostere which 3 
interacts with Tyr228 and Arg283 residues that are responsible for recognizing 4 
the carboxylate group of D-amino acid substrates. The majority of DAO inhibitors 5 
also contain an aromatic ring despite DAO’s ability to oxidize a wide range of 6 
neutral D-amino acids including those with an aliphatic chain [16, 17]. This is at 7 
least partially due to the ability of the aromatic ring to form a π-π interaction with 8 
FAD’s isoalloxazine ring [18]. According to the structural studies, the aromatic 9 
ring of benzoate and its derivative are stacked with the side chain of Tyr224 10 
[18-20]. However, other inhibitors and products including 11 
4H-thieno[3,2-b]pyrrole-5-carboxylic acid (TPC), 12 
4-(4-chlorophenethyl)-1H-pyrrole-2-carboxylic acid (CPC) and imino DOPA are 13 
not stacked with Tyr224 because the side chain of Tyr224 moves away from the 14 
active site [21, 22]. The stacked and displaced states of Tyr224 are referred to 15 
as S and D states, respectively, in this paper. The conformational flexibility of 16 
Tyr224 plays a critical role in the structural plasticity of the substrate-binding site 17 
of DAO, which catalyzes a wide range of D-amino acid substrates. In the D state, 18 
an additional pocket (referred to as the secondary pocket) is created as a result 19 
of the movement of Tyr224 to accommodate DAO inhibitors/products with a 20 
branched side chain (see Fig. 1B, D). Although the precise mechanism by which 21 
the conformation of Tyr224 is regulated is poorly understood, the secondary 22 
pocket has been exploited in a number of new DAO inhibitors containing a 23 
branched chain [22-24].  24 
   In a search for new scaffolds that inhibit DAO, we screened a variety of 25 
aromatic carboxylic acids. Among them, thiophene-2-carboxylic acid 1a and 26 
thiophene-3-carboxylic acid 2a (Table 1) exhibited low micromolar inhibitory 27 
potency with IC50 values of 7.8 µM and 4.4 µM, respectively. Herein we report 28 
structure-activity relationship (SAR) studies on the two thiophene-based 29 
scaffolds as well as X-ray crystallographic analysis and molecular dynamics 30 
simulations of the complex between thiophene-based compounds and DAO to 31 
elucidate the mechanism underlying their potent interactions.  32 
 33 
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2. Results 1 
2.1. Inhibition of D-amino acid oxidase by low molecular weight thiophene 2 
carboxylic acids 3 
   Given that a number of D-amino acid oxidase (DAO/DAAO) inhibitors 4 
reported to date are aryl carboxylic acids, we screened a variety of molecules in 5 
this category in a search for new scaffolds that inhibit DAO. Our screening 6 
efforts identified thiophene-2-carboxylic acid 1a and thiophene-3-carboxylic acid 7 
2a as low micromolar DAO inhibitors with IC50 values of 7.8 µM and 4.4 µM, 8 
respectively. While compound 2a was previously reported as a DAO inhibitor 9 
[25], compound 1a represents a new scaffold for DAO inhibition. Although other 10 
aryl carboxylic acids were previously reported to exhibit substantially higher 11 
inhibitory potency, the low molecular weights of these compounds present 12 
attractive structural features as lead compounds and prompted us to evaluate 13 
their analogs in the DAO assay. In the first phase of SAR studies, we examined 14 
analogs with minimal changes in molecular size. All compounds but one 15 
(compound 1j) were commercially available. As shown in Scheme 1, compound 16 
1j was obtained by fluorination of aldehyde 3 followed by hydrolysis of the 17 
methyl ester group.  18 
   The results are summarized in Table 1. Among compounds with the 19 
thiophene-2-carboxylic acid scaffold, many of the 5-substituted analogs, 20 
particularly those with a small substituent, potently inhibited DAO. For instance, 21 
5-fluoro (1b), 5-chloro (1c) and 5-bromo (1d) analogs exhibited substantial 22 
improvement compared to the parent compound 1a. While 5-methyl (1e) was 23 
found to be nearly as potent as 1a, a gradual decrease in potency was seen with 24 
the increase in the size of the 5-substituents as shown by 5-difluoromethyl (1f) 25 
and 5-trifluoromethyl (1g) analogs. Inhibitory activity was completely abolished 26 
when a formyl group was incorporated into the 5-position (1h). Small 27 
substituents were also well tolerated in the 4-position as seen for 1i and 1j. 28 
Interestingly, 4,5-disubsituted analogs such as 1k and 1l represented the most 29 
potent DAO inhibitors within the thiophene-2-carboxylic acid series with IC50 30 
values of 0.09 and 0.36 µM, respectively. In contrast, any substitution at the 31 
3-position appears to be detrimental to inhibitory activity as neither 3-fluoro (1n) 32 
nor 3-methyl (1o) analogs inhibited DAO. Incorporation of carboxylic acid 33 
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bioisosteres such as tetrazole (1p and 1q) and boronic acid (1r) into the 1 
2-position also resulted in a complete loss of potency. As for the analogs of2 
thiophene-3-carboxylic acid 2a, 5-chloro (2b) and 5-methyl (2c) derivatives 3 
showed substantially improved potency as compared to the parent compound 4 
2a. Indeed, 5-chlorothiophene-3-carboxylic acid 2b was the most potent 5 
thiophene-carboxylic acid-based DAO inhibitors with an IC50 value of 0.04 µM. 6 
2,5-Dichloro analog 2d, however, exhibited much weaker inhibitory potency. 7 
8 
2.2. Preference for the S state in the complexes with 1c and 2b 9 
   For a better understanding of the good potency of low molecular thiophene 10 
carboxylic acids, we determined the crystal structures of the 1c-DAO and 11 
2b-DAO complexes (Supplementary Table 1, Figs. 1, 2). We found that the 12 
thiophene rings of the thiophene-2-carboxylic 1c and thiophene-3-carboxylic 2b 13 
acid analogs are stacked with the benzene ring of Tyr224. Thus, both of the 14 
complexes are in the S state in which the formation of the secondary pocket is 15 
lost due to the movement of Tyr224 (Fig. 1). The shapes and locations of 1c and 16 
2b in the complexes are almost superimposable, with the exception of the sulfur 17 
atom of the thiophene ring (Fig. 2). Slight differences were observed for the 18 
shapes of the thiophene rings and the orientations of the carboxylate and 19 
chlorine atom. These may cause the difference in the IC50 values between 1c 20 
and 2b (Supplementary Fig. 1). 21 
   To assess the stability of the S state conformation, we performed all-atom 22 
molecular dynamics (MD) simulations using the dimer crystal structure of the 23 
2b-DAO complex as an initial structure. We measured the distance between the 24 
centroids of the thiophene ring of 2b and benzene ring of Tyr224 to judge 25 
whether Tyr224 was in the S or D state. The crystal structure of the 2b-DAO 26 
complex shows a distance of ~4 Å between the two centroids. Based on visual 27 
inspection of the trajectories of the 2b-DAO complex, we defined the S state as 28 
having a ~4 Å distance between the two centroids and the D state as having a 29 
distance that was ≥ ~5 Å . 30 
   The distance between the centroids of the thiophene ring of 2b and benzene 31 
ring of Tyr224 of Chain A was ~4 Å most of the simulation time, while it 32 
occasionally became ≥ 5 Å (Fig. 3A). Thus the S state was dominant in the 33 
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equilibration between the S and D states. We measured the corresponding 1 
distance in Chain B as well in the same MD run; the results were reproducible 2 
(Supplementary Fig. 2). Repeated MD runs again gave similar results. 3 
   In contrast, the crystal structure of the TPC-DAO complex (PDB code: 3znn) 4 
shows the D state as seen in the imino DOPA-DAO complex [21, 22]. The 5 
secondary pocket in the TPC-DAO complex is unoccupied, because TPC is a 6 
planar molecule without a branched side chain (Supplementary Table 2). Thus, 7 
it would be possible to form the S state for the TPC-DAO complex without a 8 
steric clash between TPC and DAO’s residues including Tyr224. However, MD 9 
using 3znn as an initial structure indicated that the distance between the 10 
centroids of the pyrrole ring of TPC and benzene ring of Tyr224 remained ~5 Å 11 
most of the time (i.e. the D state) (Fig. 3B). Repeated MD runs gave similar 12 
results reproducibly (Supplementary Fig. 3). 13 
   To exclude the possibility that the initial structures biased the results above, 14 
we performed additional MD runs with a virtual initial state in which 2b was 15 
substituted for TPC in the D state TPC-DAO complex (Fig. 3C, Supplementary 16 
Fig. 4). The results showed that the S state became dominant within a few 17 
nanoseconds after the simulations were initiated. Conversely, MD runs with an 18 
initial state in which TPC was substituted for 2b in an S state structure showed 19 
that the D state became dominant over time (Fig. 3D, Supplementary Fig. 5). 20 
These simulations suggest that the S state is thermodynamically preferred for 21 
the 2b-DAO complex while DAO adopts the D state when TPC is bound to its 22 
active site. 23 
24 
2.3. Thiophene carboxylic acids containing a branched chain as DAO 25 
inhibitors 26 
   In light of the previous findings that some DAO inhibitor scaffolds benefit from 27 
an added branched side chain that occupies the secondary pocket, we 28 
examined whether such a modification can also improve the inhibitory potency of 29 
the thiophene carboxylic acid scaffolds. The previously reported SAR studies 30 
indicate that the incorporation of a side chain to the position across from the 31 
carboxylate attached carbon is most effective in other aryl carboxylic acid-based 32 
DAO inhibitors. This prompted us to evaluate 4- or 5-substituted derivatives of 33 
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thiophene-2-carboxylic acid (compounds 1s-w) as well as 5-substituted 1 
derivatives of thiophene-3-carboxylic acid (compounds 2e-f). While some of 2 
these compounds were commercially available, compounds 1u, 1w, and 2f were 3 
synthesized using bromothiophenes as starting materials. The key steps 4 
involved in the synthesis include Sonogashira coupling and subsequent catalytic 5 
hydrogenation as illustrated in Schemes 2 and 3.  6 
   As summarized in Table 2, none of these compounds showed substantial 7 
inhibitory activity against DAO. The lack of potency seen with these compounds 8 
represent a sharp contrast to other aryl carboxylic acid scaffolds that benefited 9 
from side chain incorporation. For example, a 4-substituted pyrrole-2-carboxylic 10 
acid discovered by Sunovion, SEP-137, inhibits DAO with a markedly higher 11 
potency [22] than the unsubstituted pyrrole-2-carboxylic acid [26]. Similar 12 
structural modifications to 1a and 2a, however, led to a complete or significant 13 
loss of potency as demonstrated by compounds 1u, 1w, and 2f. It is worth noting 14 
that a much smaller substituent such as ethyl group is sufficient enough to 15 
eliminate the ability to inhibit DAO as seen with compounds 1s, 1v, and 2e even 16 
though the corresponding methyl substituted derivatives 1e, 1i, and 2c showed 17 
potent DAO inhibition (Table 1). These results suggest that DAO is incapable of 18 
accommodating thiophene carboxylic acids with a branched side chain larger 19 
than a methyl group. The S state observed in the co-crystal structures of DAO 20 
with 1c and 2b appears to have little flexibility in responding to the branched side 21 
chain added to the thiophene ring by shifting to the D state and creating the 22 
secondary binding pocket.  23 
 24 
2.4. Mechanism to stabilize the S state 25 
   We calculated the binding free energy (ΔGbind) by molecular mechanics 26 
energies combined with the generalized Born and surface area (MM/GBSA) 27 
using MD trajectories to compare ΔGbind with ΔGexp that was derived from 28 
experimental IC50 (Table 3). ΔGbind and ΔGexp were in good agreement with each 29 
other for the interactions between 2b and DAO and between TPC and DAO. The 30 
energy decomposition of ΔGbind on a per residue basis calculated that the 31 
contribution of Tyr224 to ΔGbind was greater in the 2b-DAO interaction than in 32 
the TPC-DAO interaction. We found a notable difference in ΔGvdw,Y224 between 33 
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the 2b-DAO and TPC-DAO interactions (Table 4). This suggests that Tyr224 1 
contributes to the interaction with low molecular thiophene carboxylic acid-based 2 
inhibitors primarily through hydrophobic interactions. 3 
   To evaluate the contributions of hydrogen bonds (H-bonds) to the 2b-DAO 4 
and TPC-DAO interactions, occupancy of each H-bond between molecules 5 
around the active site was calculated (Fig. 4A). Characteristic differences 6 
between these interactions were observed in the H-bonds between the inhibitors 7 
and Gly313 and between H2O and Tyr224. In the 2b-DAO complex, a H-bond 8 
network composed of Gln53, Pro54, His217, Tyr224, Gly313 and bridging H2O 9 
molecules contributed to stabilization of the S state (Fig. 4B). In contrast, a 10 
H-bond network including Tyr224 was not that extensive in the TPC-DAO11 
complex and partly explaining the preferred D state for this complex (Fig. 4C). 12 
   Taken together the MM/GBSA and H-bond analyses suggest that the 13 
2b-Tyr224 interaction and formation of the H-bond network around Tyr224 were 14 
driving forces to form the S state. This was supported by a finding that Tyr224 15 
underwent the largest conformational change among the inhibitor-interacting 16 
residues in the comparison of the structures of the S and D states (Fig. 5A). 17 
Leu51 and His217 also changed their conformations as a result of direct 18 
interactions with the inhibitors but to a lesser extent. Although the extent of 19 
conformational changes of Tyr55 and Ile223 appeared significant, these 20 
changes were indirectly influenced by the binding of the inhibitors. Consequently, 21 
Loop 216228 (refereed to as the lid) and Loop 53-62 approached each other in 22 
the 1c-DAO and 2b -DAO complexes. These structural changes were 23 
accompanied by a closing of a cleft between the lid and Loop 53-62 to sequester 24 
the substrate binding pocket from the surrounding environment (Fig. 5B). In 25 
contrast, the cleft is half-open with the lid relaxed in the TPC-DAO complex, in 26 
which water molecules can pass through from the inside of the pocket to the 27 
surrounding environment (Fig. 5C). 28 
   As a result of the closing of the cleft, the substrate-binding pockets of the 29 
1c-DAO and 2b-DAO complexes appeared to shrink compared with the 30 
complexes in the D state including the TPC-DAO complex (Tables 5 and 6). 31 
The extent of shrinkage was the greatest in the 2b-DAO complex. In addition, 32 
comparison between the averages throughout MD trajectories also indicated a 33 
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 The highly potent DAO/DAAO inhibitors 1c and 2b derived from the 5 
thiophene-2-carboxylic acid and thiophene-3-carboxylic acid scaffolds, 6 
respectively, allowed us to investigate the structural basis for the potent DAO 7 
inhibition achieved by such small molecules. Crystal structures and MD analysis 8 
of DAO in complex with the thiophene-based inhibitors suggested that the 9 
complexes prefer the S state and that the formation of the S state is driven by 10 
direct interactions of Tyr224 with the inhibitors and H2O. In contrast, the D state 11 
was preferred in the TPC-DAO complex during our MD simulations as shown in 12 
the crystal structure [22]. Given that the D state is preferred by TPC despite the 13 
lack of a side chain, it is conceivable that the core scaffold rather than the 14 
presence or absence of a branched side chain dictates whether the S or D state 15 
is adopted. Further evidence supporting this notion is co-crystal structures of 16 
DAO with 3-hydroxypyridin-2(1H)-one (PDB code: 3w4i) [23]. Even though the 17 
unsubstituted 3-hydroxypyridin-2(1H)-one is small enough to fit into the active 18 
site of the S state structure, the co-crystal structure adopts the D state with a 19 
vacant secondary pocket. One notable structural difference between S and D 20 
state-inducing inhibitors is the presence/absence of a hydrogen bond donor that 21 
can interact with the carbonyl oxygen of Gly313 [23]. In addition, an additional 22 
MD run with a virtual complex in which 2c was substituted for 2b in the 2b-DAO 23 
complex preferred the S state (Supplementary Fig. 6), supporting the notion 24 
that the scaffold dictates whether the S or D state is adopted. The precise 25 
mechanism by which DAO adopts the S or D state needs further investigation. 26 
   The energy decomposition of ΔGbind indicated that the hydrophobic 27 
interaction of 2b-Tyr224 was stronger than that of TPC-Tyr224. In addition, the 28 
substitution of a halogen for a methyl moiety in the thiophene ring showed 29 
increased potency. These suggested that the π-π interaction plays a role in the 30 
interaction between Tyr224 and thiophene-based inhibitors. The side chain of 31 
Tyr224 is electron-donating [27]. Thus, it is inferred that the substitution of a 32 
Kato et al. 
 
 10 
halogen increased potency because the LUMO level of the thiophene ring 1 
decreased due to electron-withdrawing effect of the halogen.  2 
   A number of scaffolds that promote the formation of the D state have been 3 
published to date. Many of these inhibitors showed potent inhibitory activity by 4 
exploiting the secondary pocket with a large branched chain in combination with 5 
a H-bond with Gly313 [22-24]. In contrast, our thiophene-based inhibitors 6 
including 1c and 2b showed low nanomolar inhibitory potency without relying on 7 
the secondary pocket and H-bond with Gly313, but instead by forming a strong 8 
stacking interaction with Tyr224. Indeed, the cleft between the lid and Loop 9 
53-62 was tightly closed in our S state structures, presenting a sharp contrast to 10 
the D state structures accommodating the half-open cleft. Moreover, a H-bond 11 
network including Tyr224 and H2O was shown to be extensive in the S state 12 
contributing to the closing of the cleft. It appears difficult to accommodate a large 13 
branched chain in the S state in which the cleft is closed due to the loss of the 14 
secondary pocket. This accounts for the substantial loss of potency caused by 15 
the introduction of a large branched chain to the thiophene ring of either the 16 
2-carboxylic acid or the 3-carboxylic acid scaffolds.  17 
 18 
4. Conclusions 19 
   Taken together, the present results suggest that the formation of the S state 20 
is driven by the concerted action of the residues around the cleft including 21 
Tyr224 and thiophene carboxylic acid scaffolds in alliance with solvent 22 
molecules. The mechanism by which the thiophene-based inhibitors achieve 23 
potent DAO inhibition is distinct from that of the D-state promoting inhibitors 24 
which exploit the secondary pocket. These findings collectively highlight two 25 
distinct structural optimization approaches to DAO inhibitors depending on how 26 
a given pharmacophore affects the position of Tyr224. For those inducing the S 27 
state, as seen with 1a and 2a, the addition of a branched chain unlikely results in 28 
improvement of inhibitory potency. The primary focus of the structural 29 
optimization strategy should be to preserve the S state by avoiding sterically 30 
hindered substituents. On the other hand, pharmacophores promoting the D 31 
state can take full advantage of the secondary pocket generated by the 32 
movement of Tyr224 by incorporating a branched chain. These insights should 33 
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be of particular importance in future efforts to optimize DAO inhibitors with novel 1 
scaffolds.  2 
 3 
5. Experimental section  4 
5.1. Chemistry 5 
   All solvents were reagent grade or HPLC grade. Melting points were 6 
obtained on a Mel-Temp apparatus and are uncorrected. 1H NMR spectra were 7 
recorded at 400 MHz. The HPLC solvent system consisted of distilled water and 8 
acetonitrile, both containing 0.1% formic acid. Preparative HPLC purification was 9 
performed on an Agilent 1200 Series HPLC system equipped with an Agilent 10 
G1315D DAD detector using a Phenomenex Luna 5 µm C18 (2) column (21.2 11 
mm × 250 mm, 5 µm) with a gradient of 40% ACN/60% H2O for 5 minutes 12 
followed by an increase to 100% ACN/0% H2O over 40 minutes and a 13 
continuation of 100% ACN/0% H2O until 50 minutes at a flow rate of 15 mL/min. 14 
Analytical HPLC was performed on an Agilent 1200 Series HPLC system 15 
equipped with an Agilent G1315D DAD detector (detection at 220 nm), and an 16 
Agilent Quadrupole 6120 LC-MS with electrospray ionization (ESI) source. The 17 
analytical HPLC conditions involve a gradient of 20% ACN/80% H2O for 0.25 18 
minutes followed by an increase to 85% ACN/15% H2O over 1.75 minutes and 19 
continuation of 85% ACN/15% H2O until 4 minutes (detection at 220 nm) with a 20 
Luna C18 column (2.1 mm × 50 mm, 3.5 m) at a flow rate of 0.75 mL/min. All 21 
final compounds tested were confirmed to be of ≥95% purity by the HPLC 22 
methods described above. Compounds 1a, 1c-e, 1i, 1o, and 2d were purchased 23 
from Aldrich. Compounds 1b and 2b were purchased from Ark Pharma, Inc. 24 
Compound 1g was purchased from Enamine. Compounds 1h and 1r were 25 
purchased from TCI America. Compounds 1m and 1q were purchased from Alfa 26 
Aesar. Compounds 1n and 1p were purchased from Parkway Scientific and 27 
ASDI, Inc., respectively. Compounds 2a, 2c, and 1s were purchased from Matrix 28 
Scientific. Compound 1t and 2e were purchased from Oakwood Chemical and 29 
Chembridge, respectively. Synthesis of compounds 1f [28], 1k [29], 1l [30], and 30 
1v [31] were previously reported.  31 
5.1.1. Synthesis of 4-(difluoromethyl)thiophene-2-carboxylic acid (1j).  32 
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   To a solution of methyl 4-formylthiophene-2-carboxylate 3 (0.18 g, 1.06 1 
mmol) in dichloromethane (7 mL) at rt was added deoxo-fluor (0.27 g, 1.22 2 
mmol) via syringe. After 4 h of stirring, the reaction was quenched by a careful 3 
addition of sat. NaHCO3. The compound was extracted twice with 4 
dichloromethane. The combined organic layers was dried over sodium sulfate 5 
and concentrated to give an oil which was purified by silica gel column (eluent: 6 
10% EtOAc in hexanes) to afford 0.075 g (37% yield) of methyl 7 
4-(difluoromethyl)thiophene-2-carboxylate 4 as a colorless oil. To a solution of 4 8 
(0.07 g, 0.36 mmol) in a 1:1 mixture of dioxane and water (4 mL) was added 1 N 9 
aqueous solution of sodium hydroxide (1 mL). The reaction was heated at 10 
100 °C for 1 h. Upon completion, the reaction mixture was concentrated in vacuo. 11 
The resulting material was acidified with aqueous 10% KHSO4 solution to pH~4. 12 
The product was extracted with EtOAc. The organic layer was washed with brine, 13 
dried over Na2SO4, and concentrated to give 0.065 g (quantitative yield from 4) 14 
of 4-(difluoromethyl)thiophene-2-carboxylic acid 1j as a light yellow solid; mp 15 
102 °C. 1H NMR (CDCl3) δ 6.56 (t, J = 56.3 Hz, 1H), 7.85 (m, 1H), 7.97 (m, 1H). 16 
LCMS: retention time 1.58 min, m/z 179.1 [M + H]+. 17 
5.1.2. Synthesis of 5-phenethylthiophene-2-carboxylic acid (1u) 18 
   To a solution of methyl 5-bromothiophene-2-carboxylate 5u (0.45 g, 2.04 19 
mmol) in diisopropylamine (10 mL) were added triphenylphosphine (0.21 g, 0.80 20 
mmol), Pd(PhCN)2Cl2 (0.15 g, 0.39 mmol) and copper (I) iodide (0.076 g, 0.40 21 
mmol). Phenylacetylene (0.4 g, 3.92 mmol) was then added under N2 and the 22 
reaction was heated at 70 °C for 72 h. After cooling to rt, the reaction mixture 23 
was concentrated in vacuo and the residual material was purified by flash 24 
chromatography (eluent: 5% EtOAc/hexanes) to give 0.39 g (79% yield) of 25 
methyl 5-(phenylethynyl)thiophene-2-carboxylate 6u as a tan solid. 1H NMR 26 
(CDCl3) δ 3.92 (s, 3H), 7.24 (d, J = 3.8 Hz, 1H), 7.39-7.40 (m, 3H), 7.54 (m, 2H), 27 
7.71 (d, J = 4.0 Hz, 1H). To a solution of 6u (0.39 g, 1.61 mmol) in EtOAc (50 28 
mL) was added a spatula tip of 10% Pd/C and the mixture was shaken under 29 
hydrogen (50 psi) for 2 h. The catalyst was removed by filtration through a pad of 30 
celite and the filtrate was concentrated to give 0.33 g (83% yield) of methyl 31 
5-(phenylethynyl)thiophene-2-carboxylate 7u as a yellow oil. 1H NMR (CDCl3) δ 32 
3.00 (t, J = 7.3 Hz, 2H), 3.15 (t, J = 8.1 Hz, 2H), 3.88 (s, 3H), 6.76 (dt, J = 0.8, 3.5 33 
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Hz, 1H), 7.19 (d, J = 7.3 Hz, 2H), 7.24 (m, 1H), 7.30 (m, 2H), 7.63 (d, J = 3.8 Hz, 1 
1H). To a solution of 7u (0.33 g, 1.34 mmol) in a 1:1 mixture of water and 2 
methanol (15 mL) was added lithium hydroxide (0.080 g, 3.33 mmol) and the 3 
reaction was heated at 40 °C for 19 h. After completion of the reaction, the 4 
reaction mixture was concentrated in vacuo. The resulting material was acidified 5 
with 1N HCl to pH~2 and the resulting precipitate was filtered to give 0.29 g 6 
(93% yield) of 5-phenethylthiophene-2-carboxylic acid (1u) as an off white solid; 7 
mp 114 °C. 1H NMR (CDCl3) δ 3.01 (t, J = 7.3 Hz, 2H), 3.18 (t, J = 8.1 Hz, 2H), 8 
6.80 (dt, J = 0.8, 3.8 Hz, 1H), 7.19-7.22 (m, 2H), 7.24 (m, 1H), 7.30 (m, 2H), 7.72 9 
(d, J = 3.8 Hz, 1H). LCMS: retention time 2.63 min, m/z 233.1 [M + H]+. 10 
5.1.3. Synthesis of 4-Phenethylthiophene-2-carboxylic acid (1w). 11 
   Methyl 4-(phenylethynyl)thiophene-2-carboxylate 6w was prepared as 12 
described for the preparation of methyl 13 
5-(phenylethynyl)thiophene-2-carboxylate 6u except methyl 14 
4-bromothiophene-2-carboxylate 5w was used in place of methyl 15 
5-bromothiophene-2-carboxylate 5u and the reaction was heated at 70 °C for 18 16 
h; brown oil (38% yield). 1H NMR (CDCl3) δ 3.93 (s, 3H), 7.37-7.39 (m, 3H), 17 
7.52-7.54 (m, 2H), 7.70 (d, J = 1.3 Hz, 1H), 7.88 (d, J  = 1.3 Hz, 1H). Methyl 18 
4-phenethylthiophene-2-carboxylate (7w) was prepared as described for the 19 
preparation of methyl 5-phenethylthiophene-2-carboxylate (7u) except methyl 20 
4-(phenylethynyl)thiophene-2-carboxylate 6w was used in place of methyl 21 
5-(phenylethynyl)thiophene-2-carboxylate 6u and that the mixture was 22 
hydrogenated for 1 h at 40 psi; yellow oil (93% yield). 1H NMR (CDCl3) δ 2.92 (s, 23 
4H), 3.88 (s, 3H), 7.10 (d, J = 1.5 Hz, 1H), 7.14 (m, 2H), 7.20 (m, 1H), 7.28 (m, 24 
2H), 7.65 (d, J = 1.5 Hz, 1H). To a solution of 7w (0.17 g, 0.69 mmol) in 1:1 25 
mixture of 1,4-dioxane and water (4 mL) was added 1 N aqueous solution of 26 
sodium hydroxide (2.1 mL) and the reaction was heated for 1 h at 100 °C. Upon 27 
completion, the reaction was concentrated in vacuo. The resulting material was 28 
acidified with aqueous 10% KHSO4 solution to pH~4. The product was extracted 29 
with EtOAc, washed with brine, dried over Na2SO4, and concentrated to give 30 
0.15 g (94% yield) of 4-phenethylthiophene-2-carboxylic acid 1w as a yellow 31 
solid; mp 136 °C. 1H NMR (CDCl3) δ 2.95 (s, 4H), 7.16-7.24 (m, 4H), 7.28 (m, 32 
2H), 7.72 (d, J = 1.5 Hz, 1H). LCMS: retention time 2.84 min, m/z 233.1 [M + H]+. 33 
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5.1.4. Synthesis of 5-phenethylthiophene-3-carboxylic acid (2f). 1 
   To a solution of 5-bromothiophene-3-carboxylic acid 8 (1.0 g, 4.83 mmol) in 2 
acetonitrile (20 mL) was added potassium carbonate (3.3 g, 23.9 mmol) followed 3 
by the addition of benzyl bromide (0.63 mL, 5.30 mmol). The mixture was heated 4 
at 80 °C for 24 h and concentrated in vacuo. The resulting residue was dissolved 5 
in EtOAc and the resulting solution was subsequently washed with water, dried 6 
over Na2SO4, and concentrated to give a light yellow oil. Purification of the crude 7 
material by flash chromatography (eluent: 5% EtOAc/hexanes) afforded 0.89 g 8 
(62% yield) of benzyl 5-bromothiophene-3-carboxylate (9) as a colorless oil. 1H 9 
NMR (CDCl3) δ 5.31 (s, 2H), 7.37-7.43 (m, 5H), 7.50 (d, J = 1.5 Hz, 1H), 8.03 (d, 10 
J = 1.5 Hz, 1H). Benzyl 5-(phenylethynyl)thiophene-3-carboxylate 10 was 11 
prepared as described for the preparation of methyl 12 
5-(phenylethynyl)thiophene-2-carboxylate 6u except benzyl 13 
5-bromothiophene-3-carboxylate 9 was used in place of methyl 14 
5-bromothiophene-2-carboxylate 5u and the reaction was heated at 70 °C for 17 15 
h; brown oil (51% yield). 1H NMR (CDCl3) δ 5.33 (s, 2H), 7.36-7.39 (m, 4H), 16 
7.41-7.46 (m, 4H), 7.69 (d, J = 1.3 Hz, 1H), 8.07 (d, J = 1.3 Hz, 1H). Benzyl 17 
5-phenethylthiophene-3-carboxylate 11 was prepared as described for the 18 
preparation of methyl 5-phenethylthiophene-2-carboxylate 7u except benzyl 19 
5-(phenylethynyl)thiophene-3-carboxylate 10 was used in place of methyl 20 
5-(phenylethynyl)thiophene-2-carboxylate 6u and that the mixture was 21 
hydrogenated for 1 h at 50 psi; yellow oil (quantitative yield). 1H NMR (CDCl3) δ 22 
2.97 (t, J = 7.1 Hz, 2H), 3.10 (t, J = 8.6 Hz, 2H), 5.30 (s, 2H), 7.18-7.24 (m, 3H), 23 
7.28 (m, 3H), 7.37-7.45 (m, 5H), 7.94 (d, J = 1.3 Hz, 1H). 24 
5-Phenethylthiophene-3-carboxylic acid 2f was prepared as described for the 25 
preparation of compound 1u except benzyl 5-phenethylthiophene-3-carboxylate 26 
11 was used in place of methyl 5-phenethylthiophene-2-carboxylate 7u and the 27 
reaction was heated in 2:1 mixture of 1,4-dioxane and water at 50 °C for 17 h 28 
and the crude material was purified by preparative HPLC; white solid (53% 29 
yield); mp 126 °C. 1H NMR (CDCl3) δ 2.99 (t, J = 7.1 Hz, 2H), 3.12 (t, J = 8.3 Hz, 30 
2H), 7.19-7.24 (m, 3H), 7.29-7.33 (m, 3H), 8.02 (d, J = 1.5 Hz, 1H). LCMS: 31 
retention time 2.85 min, m/z 233.1 [M + H]+. 32 
 33 
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5.2. In vitro DAO assay 1 
   D-Serine was purchased from Bachem Biosciences Inc, horse radish 2 
peroxidase from Worthington Biochemical Corporation and o-phenylenediamine 3 
from Pierce Biotechnology, Inc. All other chemicals were obtained from 4 
Sigma-Aldrich. A reliable 96-well plate D-amino acid oxidase (DAO/DAAO) 5 
assay was developed based on previously published methods [32]. Briefly, 6 
D-serine (5 mM) was oxidatively deaminated by human DAO in the presence of 7 
molecular oxygen and flavin adenosine dinucleotide (FAD; 10 µM), to yield the 8 
corresponding α–keto acid, ammonia and hydrogen peroxide. The resulting 9 
hydrogen peroxide was quantified using horseradish peroxidase (0.01 mg/mL) 10 
and o-phenylenediamine (180 µg/mL), which turns yellowish-brown upon 11 
oxidation. DAO activity was correlated to the rate formation of the colored 12 
product, i.e., rate of change of absorbance at 411 nm. All reactions were carried 13 
out for 20 min at room temperature in a 100-µL volume in Tris buffer (50 mM, pH 14 
8.5). Additionally, stock solutions and serial dilutions of potential DAO inhibitors 15 
were made in 20:80 DMSO:buffer with a final assay DMSO concentration of 2%. 16 
 17 
5.3. X-ray crystallography 18 
   Expression, purification and crystallization of human DAO were previously 19 
described [19]. Briefly, full-length DAO protein was expressed using pET11b 20 
(Novagen) and E. coli BL21 (DE3). After disruption of cells, the extract was 21 
centrifuged, heated and fractionated with ammonium sulfate. The sample was 22 
applied to DEAE (Sigma-Aldrich) and hydroxylapatite columns (Nacalai). DAO 23 
was crystallized with 15% [w/v] PEG 4000, 0.2 M ammonium acetate, 0.1 M Na 24 
citrate at pH 8.0, and 10% [v/v] glycerol. 1c and 2b (1 mM each) were soaked 25 
into the crystals prior to X-ray diffraction experiments. Diffraction data were 26 
collected at Photon Factory AR NW12A and SPring-8 BL44XU. Scaling, 27 
molecular replacement and model building were performed with iMosfilm [33], 28 
XDS [34], MolRep [35] and Coot [36], respectively. Refinement was performed 29 
as previously described using Refmac and Phenix [37-39].  30 
 31 
5.4. Molecular dynamics 32 
   Dimer structures of the complexes of 2b-DAO (PDB code: 5zj9) and 33 
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TPC-DAO (PDB code: 3znn) retaining cofactors and water molecules were used 1 
as initial structures. The initial structure in the D state with 2b was constructed by 2 
superimposing 3znn and 5zj9 and subsequently combining the coordinates of 2b 3 
with the 3znn coordinates without TPC. The construction of the initial structure in 4 
the S state with TPC and 2c followed a similar procedure. Structure optimization 5 
and calculation of electrostatic potentials of ligands were performed with the 6 
HF/6-31G(d) basis set using Gaussian 09 [40]. Atomic charges and atom types 7 
were assigned using Antechamber [41]. Generalized Amber force field (GAFF) 8 
implemented in the LEaP module of the Amber suite was used to parameterize 9 
ligands [42, 43]. Ionization states of charged residues were calculated according 10 
to ProPKA [44]. The Amber ff14SB force field was used for polypeptide chains. 11 
All systems were solvated in TIP3P water boxes with the minimum margin of 10 12 
Å using solvate1.0 and the LEaP module [45]. Cl- was added to neutralize the 13 
systems. Na+ and Cl- were further added to adjust the salt concentration of the 14 
systems to 0.15 M.  15 
   Energy minimization was performed using Amber 14 with 10-Å cut-off for the 16 
non-bonded interactions [43]. 5000 steps of steepest descent minimization were 17 
performed followed by 5000 steps of conjugate gradient minimization using the 18 
Particle Mesh Ewald method under constant-volume and periodic boundary 19 
conditions. An initial minimization was performed for solvent molecules and 20 
hydrogen atoms followed by minimization for all atoms in the systems.  21 
   The systems were gradually heated from 0 to 310 K under constant-volume 22 
conditions. The temperature was controlled using Langevin dynamics with a 23 
collision frequency of 2.0 ps-1. Step size was set to 2 fs with fixed bond lengths 24 
involving all hydrogen atoms using the SHAKE algorithm [46]. Motions of all 25 
solute atoms except hydrogens were restricted during the heating process. 26 
Equilibration and production MD simulations were performed under 1 atm at 310 27 
K without motion restrictions for all atoms as previously described [47, 48]. 28 
Equilibration of the systems was monitored as shown in Supplementary Figs. 29 
7-11. 30 
 31 
5.5. Binding free energy calculations 32 
   Calculations of binding free energy (ΔGbind) of inhibitors to DAO were 33 
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performed by the molecular mechanics energies combined with the generalized 1 
Born and surface area (MM/GBSA) method implemented in the AmberTools14 2 
suite [49, 50]. Binding free energy (ΔGbind) was previously defined as below [48, 3 
51, 52].  4 
ΔGbind = ΔGMM + ΔGsolv = ΔHbind - TΔSMM 5 
where ΔGMM, ΔGsolv, ΔHbind and TΔSMM refer to molecular mechanics free energy, 6 
solvation free energy, binding enthalpy and entropy term, respectively. 7 
ΔGMM = ΔEMM - TΔSMM 8 
where ΔEMM refers to enthalpy in the gas phase upon complex formation.  9 
ΔHbind = ΔEMM + ΔGsolv 10 
ΔEMM =ΔEvdw + ΔEelec 11 
where ΔEvdw and ΔEelec refer to van der Waals and electrostatic interaction 12 
energies, respectively. 13 
ΔGsolv = ΔGsolvpolar + ΔGsolvnonpolar  14 
where ΔGsolvpolar and ΔGsolvnonpolar refer to polar and nonpolar contributions of 15 
solvation free energy, respectively.  16 
ΔGexp was calculated from the IC50 using the following relations [51].  17 
ΔGexp = ~ RT ln IC50 18 
Where R and T are the ideal gas constant and absolute temperature, 19 
respectively.  20 
   TΔSMM was calculated using the quasi-harmonic approximation [53]. H-bond 21 
occupancy was calculated using CPPTRAJ implemented in the AmberTools14 22 
suite [54].  23 
 24 
5.6. Data availability 25 
   The atomic coordinates of inhibitor-DAO complexes were deposited in the 26 
Protein Data Bank. The access codes are 5zja (1c-DAO complex) and 5zj9 27 




   This research was supported in part by a grant for Enzyme Research from 32 
the Japan Foundation for Applied Enzymology, a research grant from the 33 
Kato et al. 
 
 18 
National Institutes of Health (R01MH091387) and JSPS KAKENHI Grant 1 
Number 18K06580. We thank the beamline staff at the Photon Factory (proposal 2 
No: 2013G075) and the SPring-8 BL44XU (Proposal No. 2015A6537 3 




Appendix A. Supplementary data 8 
   Supplementary data related to this article can be found at 9 
 10 
 11 
Figure legends  12 
 13 
Fig 1 Structural change of Tyr224 in response to bound inhibitors 14 
A, C: Tyr224 in the S state. In the complex structure of 2b-DAO, Tyr224 (yellow) 15 
is stacked with the thiophene ring of the inhibitor. The secondary pocket is lost in 16 
this state.  17 
B, D: Tyr224 in the D state. In the complex structure between CPC and DAO, the 18 
side chain of Tyr224 is shifted to allow an additional pocket (i.e. the secondary 19 
pocket) to appear, which accommodates the branched side chain of the inhibitor 20 
[22](PDB code: 3zno). A yellow dashed circle indicates the secondary pocket. 21 
The structure and IC50 value of CPC are shown in Supplementary Table 2. 22 
 23 
Fig 2 The active sites of the 1c-DAO and 2b-DAO complexes  24 
A: The active site of the crystal structure of the 1c-DAO complex 25 
B: The active site of the crystal structure of the 2b-DAO complex 26 
C: Superimposition of the 1c-DAO (pale cyan) and 2b-DAO (yellow) complexes 27 
 28 
Fig 3 Distance between the benzene ring of Tyr224 and the 5-membered 29 
rings of the DAO inhibitors  30 
All panels in this figure indicate the results for Chain A of DAO dimers. The 31 
results for Chain B are shown in Supplementary Figs. 1-4. On top of the panels, 32 
initial and final states under individual simulation conditions are illustrated. An 33 
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arrowhead in each panel indicates the distance between the centroids of the 1 
rings of Tyr224 and inhibitors in the initial structure. 2 
A: Distance between the centroids of the rings of Tyr224 and 2b during a MD 3 
simulation. The initial structure for this run was a dimer crystal structure of the 4 
2b-DAO complex, which is in the S state. The average distance between the 5 
centroids throughout trajectories was 4.04 Å. 6 
B: Distance between the centroids of the benzene ring of Tyr224 and pyrrole ring 7 
of TPC during a MD simulation. The initial structure for this run was a dimer 8 
crystal structure of the TPC-DAO complex, which is in the D state. The structure 9 
and IC50 value of TPC are shown in Supplementary Table 2. 10 
C: Distance between the centroids of the rings of Tyr224 and 2b during a MD 11 
simulation. The initial structure for this run was a hypothetical structure in which 12 
a D state structure of DAO derived from the TPC-DAO complex structure was 13 
combined with the coordinates of 2b.  14 
D: Distance between the centroids of the rings of Tyr224 and TPC during a MD 15 
simulation. The initial structure for this run was a hypothetical structure in which 16 
an S state structure of DAO derived from the 2b-DAO complex structure was 17 
combined with the coordinates of TPC.  18 
 19 
Fig 4 Analysis of H-bond networks around the active site 20 
A: Occupancy of H-bonds between inhibitors and DAO (left) and between H2O 21 
and DAO (right). The listed H-bonds between H2O and DAO are those bridging 22 
Tyr224 and other DAO residues via H2O.  23 
B: H-bond networks around the active site in the 2b-DAO complex depicted 24 
based on Panel A (Occupancy > 0.4). Cyan lines and red balls indicate H-bonds 25 
and oxygen atoms of H2O molecules, respectively.  26 
C: H-bond networks around the active site in the TPC-DAO complex depicted 27 
based on Panel A (Occupancy > 0.4).  28 
 29 
Fig 5 Difference of S and D state structures 30 
A: Loops around the active sites of superimposed DAO structures in complex 31 
with 2b (pale cyan) and TPC (yellow).  32 
B: The 2b-DAO complex viewed from the surface of the protein molecule. 33 
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Orange spheres and blue balls indicate 2b and oxygen atoms of H2O, 1 
respectively. Transparent surface in pale cyan corresponds to the lid and Loop 2 
53-62.  3 
C: The TPC-DAO complex viewed from the surface of the protein molecule. 4 
Orange spheres and blue balls indicate TPC and oxygen atoms of H2O, 5 
respectively. Transparent surface in yellow corresponds to the lid and Loop 6 
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(a) IniDal structure: Crystal structure of DAO in complex with JH449 chain A
Distance in the crystal structure: 3.86 Å 
(b) IniDal structure: Crystal structure of DAO in complex with 4WL (3znn)
Distance in the crystal structure: 4.67 Å 

































0 204 8 12 16



















































































































Tables and Schemes 
Table 1 Inhibition of human DAO by low molecular weight thiophene 
carboxylic acids 
Cmpd Structure IC50 (µM) 
1a 7.8 ± 1.7 
1b 1.4 ± 0.1 
1c 0.72 ± 0.07 
1d 1.3 ± 0.2 
1e 4.6 ± 0.5 
1f 8.8 ± 1.3 
1g 21 ± 2 
1h >100
1i 1.3 ± 0.2 
1j 1.3 ± 0.1 
1k 0.090 ± 0.016 
1l 0.36 ± 0.04 
33 






2a 4.4 ± 0.6 
2b 0.036 ± 0.007 
2c 0.22 ± 0.02 
2d 27 ± 1 
34 
Table 2 Inhibition of human DAO by thiophene carboxylic acids containing 
a branched chain  
Cmpd Structure IC50 (µM) 





1w 55 ± 2 
2a 4.4 ± 0.6 
2e 38 ± 3 
2f 39 ± 2 
35 
Table 3 Calculated binding free energies and their components (kcal mol-1) 
for the 2b-DAO and TPC-DAO complexes 
2b-DAO Chain A 2b-DAO Chain B TPC-DAO chain A TPC-DAO chain B 
ΔEvdw -21.4 ± 0.2 -20.5 ± 0.3 -21.4 ± 0.2 -21.6 ± 0.2
ΔEelec 52.9 ± 0.5 43.3 ± 0.6 39.9 ± 0.6 32.3 ± 0.5 
ΔEMM 31.5 ± 0.5 22.8 ± 0.5 18.5 ± 0.6 10.6 ± 0.5 
TΔSMM -26.1275 -26.4850 -26.6865 -27.2518
ΔGMM 57.6 49.3 45.2 37.9 
ΔGsolvpolar -64.4 ± 0.5 -57.1 ± 0.5 -51.9 ± 0.6 -44.4 ± 0.5
ΔGsolvnonpolar -2.840 ± 0.007 -2.781 ± 0.007 -2.788 ± 0.008 -2.757 ± 0.009
ΔGsolv -67.2 ± 0.5 -59.9 ± 0.5 -54.7 ± 0.6 -47.1 ± 0.5
ΔGbind  -9.6 -10.6 -9.5 -9.2
ΔGexp a -10.63 -11.68
ΔGY224b -1.57 ± 0.03 -1.44 ± 0.03 -0.69 ± 0.03 -0.73 ± 0.03
ΔGG313b -0.33 ± 0.03 -0.55 ± 0.02 -2.02 ± 0.05 -2.04 ± 0.05
a Calculated values from IC50.  
b Results from the residue-based decomposition. 
36 
Table 4 Residue-based energy decomposition on Tyr224 (kcal mol-1) 
ΔGvdw,Y224a ΔGelec,Y224a ΔGsolvpolar,Y224a ΔGsolvnonpolar,Y224a ΔGY224a
2b-DAO 
Chain A 












-1.90 ± 0.03 1.28 ± 0.04 0.02 ± 0.03 -0.133 ± 0.001 -0.73 ±
0.03
aΔGY224 = ΔGvdw,Y224 + ΔGelec,Y224 + ΔGsolvpolar,Y224 + ΔGsolvnonpolar,Y224 
37 
Table 5 Distance between the residues that surround the active site in the 
S state.  
1c-DAOa 2b-DAOa 2b-DAOb Benzoate-DAOa 
PDB ID/MD 5zja 5zj9 MD 2du8 
Q53-H217 8.13 ± 0.06 8.28 ± 0.07 8.530 ± 0.009 8.38 ± 0.07 
Q53-Y224 9.01 ± 0.03 9.16 ± 0.04 9.080 ± 0.007 9.15 ± 0.01 
Q53-G313 4.96 ± 0.03 4.75 ± 0.06 4.685 ± 0.007 4.93 ± 0.05 
H217-G313 10.25 ± 0.10 9.95 ± 0.03 10.193 ± 0.010 10.43 ± 0.08 
a Average from all polypeptides in a unit cell 
b Average throughout the trajectories.  
Table 6 Distance between the residues that surround the active site in the 
D state.  
TPC-DAOa TPC-DAOb CPC-DAOa Imino 
DOPA-DAOa 
PDB ID/MD 3znn MD 3zno 2e82 
Q53-H217 8.36 ± 0.09 8.588 ± 0.009 8.38 ± 0.12 8.61 ± 0.09 
Q53-Y224 9.54 ± 0.04 9.667 ± 0.009 9.40 ± 0.24 9.77 ± 0.04 
Q53-G313 5.06 ± 0.01 5.102 ± 0.011 5.50 ± 0.20 5.16 ± 0.10 
H217-G313 10.52 ± 0.08 10.543 ± 0.010 11.02 ± 0.14 11.19 ± 0.13 
a Average from all polypeptides in a unit cell 
b Average throughout the trajectories.  
38 
Scheme 1. Synthesis of compound 1j. Reagents and conditions: (a) 
Deoxo-Fluor, dichloromethane, rt; (b) NaOH, 1,4-dioxane-water, 100 °C. 
Scheme 2. Synthesis of compounds 1u and 1w. Reagents and conditions: (a) 
Ph3P, Pd(PhCN)2Cl2, CuI, diisopropylamine, phenylacetylene, 70 °C; (b) 
H2/Pd-C, EtOAc, 40-50 psi, rt; (c) NaOH, 1,4-dioxane-water, 100 °C. 
Scheme 3. Synthesis of compound 2f. Reagents and conditions: (a) BnBr, 
K2CO3, acetonitrile, 80 °C; (b) Ph3P, Pd(PhCN)2Cl2, CuI, diisopropylamine, 
phenylacetylene, 70 °C; (c) H2, Pd/C, EtOAc, 40 psi; (d) NaOH, 
1,4-dioxane-water, 100 °C. 
